 II. Determine the complete and partial response rate in patients with selected non-Hodgkins lymphoma e.g., indolent B-cell, mantle cell, intermediate grade B-cell, and TNK-cell, Hodgkins lymphoma, or multiple myeloma treated with this drug. 